Navigation Links
Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results
Date:2/14/2008

(NSCLC) patients who have tumor progression after having previously

benefited from EGFR inhibitors.

-- Presented comprehensive phase 1 data for XL880 in June, and published

abstracts on phase 1 data for XL184, XL647 and XL880.

-- Reported phase 2 proof-of-concept data for XL647 as first-line therapy

for NSCLC in September.

-- Presented phase 1 data for second-generation MET inhibitor XL184,

selective PI3K inhibitor XL147 and dual PI3K/mTOR inhibitor XL765, and

phase 2 data for XL880 in papillary renal cell carcinoma and phase 2

data for XL647 in NSCLC in October.

-- Presented encouraging phase 1 data for XL019, our selective inhibitor

of JAK2, in December.

-- Filed investigational new drug applications for four compounds: XL418

(January), XL147 (March), XL765 (April) and XL019 (May).

-- Advanced new development candidates into preclinical development,

including XL139 (Hedgehog antagonist), XL888 (HSP90 inhibitor) and

XL652 (LXR modulator).

-- Held our Third Annual Exelixis Research and Development Day in

December.

Business Development

-- Retained rights to develop and commercialize XL647 after

GlaxoSmithKline declined to exercise its option to further develop and

commercialize the compound.

-- Received notice of GlaxoSmithKline's selection of XL880 for further

development and commercialization. We expect the XL880 program to be

transferred to GlaxoSmithKline in the first quarter of 2008.

-- Presented phase 2 data for XL784 in November indicating that XL784 did

not meet its primary endpoint, and as expected, GSK chose not to

exercise its option to further develop XL784. Based on encouraging

data from a subgroup analysis, the compound may nevertheless have

potential to benefit patients with diabet
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Exelixis Announces February 14 Webcast of Its Fourth Quarter and Full Year 2007 Financial Results Conference Call
2. Exelixis Announces February 12 Webcast of Presentation at the 10th Annual BIO CEO and Investor Conference
3. Exelixis Announces January 31 Webcast of Presentation at the 2008 Wachovia Healthcare Conference
4. Exelixis Announces Senior Management Promotions
5. Exelixis Announces January 10 Webcast of Presentation at the 26th Annual JPMorgan Healthcare Conference
6. Exelixis Submits XL139 Diligence Report to Bristol-Myers Squibb
7. Reminder: Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
8. Exelixis Announces November 28 Webcast of Presentation at the Lazard Capital Markets Fourth Annual Healthcare Conference
9. Exelixis Announces November 27 Webcast of Presentation at the 19th Annual Piper Jaffray Health Care Conference
10. Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
11. Exelixis Sells 80% Stake in Artemis to Taconic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Applying a well-known optical phenomenon called thin-film ... has demonstrated the ability to "paint" ultra-thin coatings ... promise for making future, flexible electronic devices, creating ... next-gen rocket ships and spacecraft with extremely lightweight ... in water, it becomes iridescent, revealing a myriad ...
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... and segments with highest potential revenues Do you ... updated report gives you revenue predictions for those ... For those therapies you find financial data, R&D ... analysis you get sales forecasts to 2024 at ...
(Date:9/30/2014)... Proove Biosciences , the commercial and research leader in ... test built upon research from their published P.A.I.N. Study. ... physicians with an objective way to understand theirs patient’s ... individuals. With this new test, physicians will be able ... that will affect their pain tolerance. , The P.A.I.N. ...
(Date:9/30/2014)... , September 30, 2014 ... intuitive browsing of chemistry in documents ... software solutions and consulting services for life science ... information and generate Markush structures from documents. ... organizations intellectual property, however generating and understanding Markush ...
Breaking Biology Technology:Taking thin films to the extreme 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2
... Patient wait times down; use of resources, accuracy and new patient ... ... HOUSTON, June 6 A new oncology practice management,model adapted ... access to advanced cancer care,while improving efficiency., The model, developed ...
... SOMERVILLE, N.J., June 6 ETHICON, INC. today ... of recombinant,human platelet-derived growth factor indicated as an ... ulcers., The WARNINGS section of the label ... a description of the epidemiologic data that is ...
... poultry processing ... line, including post-chill., SHREVEPORT, La., June ... that,poultry processing plants using FreshFx to acidify the scalder water ... adding FreshFx to the scalder can result in pathogen,reduction, but ...
Cached Biology Technology:US Oncology Manufacturing-Inspired Practice Management Model Producing Quality and Efficiency Improvements 2US Oncology Manufacturing-Inspired Practice Management Model Producing Quality and Efficiency Improvements 3US Oncology Manufacturing-Inspired Practice Management Model Producing Quality and Efficiency Improvements 4ETHICON, INC. Announces Revised Label For REGRANEX(R) (becaplermin) Gel 0.01% 2FreshFx(R) in Scalder Reduces Pathogens in Evisceration 2FreshFx(R) in Scalder Reduces Pathogens in Evisceration 3
(Date:9/30/2014)... threats in today,s ocean. From overfishing and pollution ... ecosystems are disappearing at unprecedented rates around the ... surrounding the island of Moorea in French Polynesia ... coral guard-crabs. New research from the National Museum ... McKeon and the museum,s predoctoral fellow Jenna Moore ...
(Date:9/29/2014)... bacteria called Clostridium ramosum , coupled with a high-fat ... published this week in mBio , the online open-access ... research team from the German Institute of Human Nutrition Potsdam-Rehbruecke ... C. ramosum gained weight when fed a high-fat ... were less obese even when consuming a high-fat diet, and ...
(Date:9/29/2014)... 1970 and 2010 populations of mammals, birds, reptiles, ... percent, says the 2014 Living Planet Report released ... loss occurs disproportionately in low-income countriesand correlates with ... In addition to the precipitous decline in wildlife ... signs about the overall health of the planet. ...
Breaking Biology News(10 mins):Smithsonian scientists discover coral's best defender against an army of sea stars 2Gut bacteria promote obesity in mice 2Half of global wildlife lost, says new WWF report 2
... suggests that the prolonged fatigue after mild exercise that ... is distinct from the inherent muscle weakness caused by ... in Nature Advance Online Publication Oct. 26, ... exercise-induced fatigue in mouse models of muscular dystrophy. Moreover, ...
... use flower scent to guide their nest-mates to good ... of London. For any animal, finding food on ... animals such as bees reduce these problems by informing ... the search. Honeybees use their waggle-dance to tell ...
... for the Rockot launcher that shall carry ESA,s GOCE ... of a failure in the guidance and navigation system ... anomaly was discovered during the spacecraft,s launch preparation tests ... to the postponement of the launch. , The cause ...
Cached Biology News:Study may explain exercise-induced fatigue in muscular dystrophies 2Study may explain exercise-induced fatigue in muscular dystrophies 3
... (MOPS Buffered) has been developed specifically for ... solution. HRP Stabilizer prevents the loss ... of the antibody or protein antigen portion ... at 0.2 microns., ,Contents: Aqueous, protein-containing ...
384 Well PCR Plate Carrier for Thermo-Sealer...
... strength adhesive system which facilitates the easy removal ... either side of the frame are of differing ... has an easy release adhesive whereas the reverse, ... bond. This means that when the coverslip is ...
These 18x18 square No.1 Corning cover glasses are made from No. 0211 zinc titania glass and are 0.16 to 0.19mm thick....
Biology Products: